When.com Web Search

  1. Ad

    related to: novartis ixiaro news update

Search results

  1. Results From The WOW.Com Content Network
  2. Novartis receives binding offer from Siemens Healthineers for ...

    www.aol.com/news/novartis-receives-binding-offer...

    (Reuters) -Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany's Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...

  3. Valneva SE - Wikipedia

    en.wikipedia.org/wiki/Valneva_SE

    Valneva along with Dynavax Technologies [11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, [12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.

  4. Novartis sues US government over Medicare drug price ... - AOL

    www.aol.com/news/novartis-sues-us-government...

    Swiss drugmaker Novartis on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine ...

  5. Novartis Appoints New Pharma Unit Head, Gives Other Updates - AOL

    www.aol.com/news/novartis-appoints-pharma-unit...

    Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates. Novartis Appoints New Pharma Unit Head, Gives Other Updates

  6. Japanese encephalitis vaccine - Wikipedia

    en.wikipedia.org/wiki/Japanese_encephalitis_vaccine

    Japanese encephalitis vaccines first became available in the 1930s. [3] One of them was an inactivated mouse brain-derived vaccine (the Nakayama and/or Beijing-1 strain), made by BIKEN and marketed by Sanofi Pasteur as JE-VAX, until production ceased in 2005.

  7. Novartis raises sales growth target to 5% a year through 2027

    www.aol.com/news/novartis-lifts-sales-growth...

    FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...

  8. Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic ... - AOL

    www.aol.com/news/novartis-nvs-q3-earnings-beat...

    Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak. Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review Skip ...

  9. Novartis Edges Higher After Confirming Sandoz Spin-Off - AOL

    www.aol.com/news/novartis-edges-higher...

    By Geoffrey Smith. For premium support please call: 800-290-4726 more ways to reach us